Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DaTscan Imaging in Aging and Neurodegenerative Disease
NCT01453127Phase 4Enrolling by invitation
- Sponsor
- Mayo Clinic
- Start
- Oct 2011
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
A Phase 4 trial of ioflupane I-123 in Alzheimer's disease (AD), dementia with Lewy bodies (DLB), frontotemporal dementia (FTD), Parkinson's disease (PD), corticobasal degeneration (CBD), sponsored by Mayo Clinic. Started Oct 2011; status: enrolling by invitation.
02
Drugs
ioflupane I-123
03
Conditions
Alzheimer's disease (AD)dementia with Lewy bodies (DLB)frontotemporal dementia (FTD)Parkinson's disease (PD)corticobasal degeneration (CBD)
Beyond the preview
Go deeper on NCT01453127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01453127.